Eli Lilly Invests $6 Billion in New Alabama Manufacturing Facility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Massive Investment: Eli Lilly has announced a plan to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, which is expected to create 3,450 manufacturing and construction jobs, significantly boosting the local economy.
- Innovative Drug Production: The facility will focus on producing small molecule synthetic and peptide medicines, including Lilly's first oral GLP-1 receptor agonist, orforglipron, which is expected to be submitted to global regulatory agencies for obesity treatment by the end of this year, enhancing the company's competitive position in this market.
- Construction Timeline and Economic Impact: Construction is anticipated to begin in 2026 and be completed by 2032, generating 3,000 construction jobs during this period, with Lilly estimating that every dollar invested will lead to four dollars in local economic activity, thereby strengthening supply chain resilience.
- Technology and Sustainability: Lilly plans to implement advanced technologies such as machine learning and digitally integrated monitoring systems in the new facility to ensure efficient production and environmental sustainability, reinforcing its manufacturing capabilities in the U.S. and supporting healthier communities.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1087.380
Low
950.00
Averages
1192
High
1500
Current: 1087.380
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
